Potential nephroprotective effects of l-carnitine against drug-induced nephropathy: A review of literature

Expert Opinion on Drug Safety

Volumn 12, Issue 4, 2013, Pages 523-543

  Jafari, Atefeh ^a   Dashti Khavidaki, Simin ^a   Khalili, Hossein ^a   Lessan Pezeshki, Mahboob ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug induced nephrotoxicity; l carnitine; Nephroprotective; Nephrotoxicity; Renoprotective

Indexed keywords

CARBOPLATIN; CARNITINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIATRIZOATE; DOXORUBICIN; GELATINASE B; GENTAMICIN; IFOSFAMIDE; METHOTREXATE; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; DRUG INDUCED DISEASE; DRUG INDUCED NEPHROTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; NEPHROTOXICITY; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; RENAL PROTECTION; REVIEW; UREA NITROGEN BLOOD LEVEL;

ANIMALS; CARNITINE; HUMANS; KIDNEY; KIDNEY DISEASES;

EID: 84879356434     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.794217     Document Type: Review

References (127)

1. Nolin TD, Himmelfarb J. Drug-induced kidney disease. In: Dipiro JT, editors. Pharmacotherapy, a pathophysiologic approach. 8th edition. Mc Graw Hill companies, Inc, New York; 2011
2. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008;78:743-50
3. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 2009;4:1275-83
4. Steiber A, Kerner J, Hoppel CL. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med 2004;25:455-73 (Pubitemid 39195071)
5. Walter JH. L-Carnitine. Arch Dis Child 1996;74:475-8 (Pubitemid 26231545)
6. Tanphaichitr V, Leelahagul P. Carnitine metabolism and human carnitine deficiency. Nutrition 1993;9:246-54 (Pubitemid 23183324)
7. Calò LA, Vertolli U, Davis PA, Savica V. L carnitine in hemodialysis patients. Hemodial Int 2012;16:428-34
8. Shores NJ, Keeffe EB. Is oral L-acyl-carnitine an effective therapy for hepatic encephalopathy? Review of the literature. Dig Dis Sci 2008;53:2330-3
9. Chapman KA, Gropman A, MacLeod E, Acute management of propionic acidemia. Mol Genet Metab 2011;105:16-25
10. Gahl WA, Bernardini I, Dalakas M, Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest 1988;81:549-60 (Pubitemid 18075251)
11. Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med 2007;20:499-502 (Pubitemid 350096953)
12. Leitch A, Williams M. The use of carnitine rather than renal replacement therapy for sodium valproate poisoning. JICS 2010;11:40-3
13. Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Neuropsychobiology 1997;35:16-23 (Pubitemid 27037718)
14. Ilias I, Manoli I, Blackman MR, L-Carnitine and acetyl-L-carnitine in the treatment of complications associated with HIV infection and antiretroviral therapy. Mitochondrion 2004;4:163-8 (Pubitemid 39549805)
15. Bonner CM, DeBrie KL, Hug G, Effects of parenteral L-carnitine supplementation on fat metabolism and nutrition in premature neonates. J Pediatr 1995;126:287-92
16. Mancuso C, Bates TE, Butterfield DA, Natural antioxidants in Alzheimer's disease. Expert Opin Investig Drugs 2007;16:1921-31 (Pubitemid 351403724)
17. Arsenian MA. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 1997;40:265-86 (Pubitemid 28008762)
18. Ferrari R, Merli E, Cicchitelli G, Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004;1033:79-91 (Pubitemid 39656740)
19. Iliceto S, Scrutinio D, Bruzzi P, Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995;26:37-80
20. Rubin MR, Volek JS, Gomez AL, Safety measures of L-carnitine L-tartrate supplementation in healthy men. J Strength Cond Res 2001;15:486-90 (Pubitemid 33658587)
21. Cruciani RA, Dvorkin E, Homel P, Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage 2006;32:551-9 (Pubitemid 44872930)
22. No authors listed. Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J 1999;20:70-6
23. Ye J, Li J, Yu Y, L-carnitine attenuates oxidant injury in HK-2 cells via ROS-mitochondria pathway. Regul Pept 2010;161:58-66
24. Li JL, Wang QY, Luan HY, Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha. J Biomed Sci 2012;19:32
25. Mutomba MC, Yuan H, Konyavko M, Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine. FEBS Lett 2000;478:19-25 (Pubitemid 30462251)
26. Chen HH, Sue YM, Chen CH, Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. Nephrol Dial Transplant 2009;24:3042-9
27. Arafa HM. Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids. Toxicology 2008;254:51-60
28. Calvani M, Benatti P, Mancinelli A, Carnitine replacement in end-stage renal disease and hemodialysis. Ann NY Acad Sci 2004;1033:52-66 (Pubitemid 39656738)
29. Miguel-Carrasco JL, Mate A, Monserrat MT, The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am J Hypertens 2008;21:1231-7
30. Tamai I, Ohashi R, Nezu J, Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998;273:20378-82 (Pubitemid 28377603)
31. Marthaler NP, Visarius T, Kupfer A, Lauterburg BH. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol 1999;44:170-2 (Pubitemid 29297065)
32. Lancaster CS, Hu C, Franke RM, Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res 2010;16:4789-99
33. Ganapathy ME, Huang W, Rajan DP, Beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 2000;275:1699-707 (Pubitemid 30060789)
34. Haschke M, Vitins T, Lude S, Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant 2010;25:426-33
35. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2010;2:2490-518
36. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009;61:223-42
37. Heuberger W, Berardi S, Jacky E, Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 1998;54:503-8 (Pubitemid 28487369)
38. Chang B, Nishikawa M, Sato E, L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 2002;405:55-64 (Pubitemid 35026166)
39. Sayed-Ahmed MM, Eissa MA, Kenawy SA, Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy 2004;50:162-70 (Pubitemid 39482545)
40. Aleisa AM, Al-Majed AA, Al-Yahya AA, Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues. Clin Exp Pharmacol Physiol 2007;34:1252-9 (Pubitemid 350013238)
41. Cayir K, Karadeniz A, Yildirim A, Protective effect of L-carnitine against cisplatin-induced liver and kidney oxidant injury in rats. Cent Eur J Med 2009;4:184-91
42. Tufekci O, Gunes D, Ozogul C, Evaluation of the effect of acetyl L-carnitine on experimental cisplatin nephrotoxicity. Chemotherapy 2009;55:451-9
43. Martinez G, Costantino G, Clementi A, Cisplatin-induced kidney injury in the rat: L-carnitine modulates the relationship between MMP-9 and TIMP-3. Exp Toxicol Pathol 2009;61:183-8
44. Uzunoglu S, Karagol H, Ozpuyan F, Protective effect of L-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats. Med Oncol 2011;28(Suppl 1):S690-6
45. Mancinelli A, D'Iddio S, Bisonni R, Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. Cancer Chemother Pharmacol 2007;60:19-26 (Pubitemid 46643713)
46. Pisano C, Pratesi G, Laccabue D, Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003;9:5756-67 (Pubitemid 37499500)
47. Ghirardi O, Lo Giudice P, Pisano C, Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 2005;25:2681-7
48. Engle DB, Belisle JA, Gubbels JA, Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin. Gynecol Oncol 2009;112:631-6
49. Altun ZS, Gunes D, Aktas S, Protective effects of acetyl-L-carnitine on cisplatin cytotoxicity and oxidative stress in neuroblastoma. Neurochem Res 2010;35:437-43
50. Baumann F, Preiss R. Cyclophosphamide and related anticancer drugs. J Chromatogr B Biomed Sci Appl 2001;764:173-92 (Pubitemid 33044665)
51. Ntali S, Bertsias G, Boumpas DT. Cyclophosphamide and lupus nephritis: when, how, for how long? Clin Rev Allergy Immunol 2011;40:181-91
52. Sayed-Ahmed MM. Role of carnitine in cancer chemotherapy-induced multiple organ toxicity. Saudi Pharm J 2010;18:195-206
53. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001;24:19-38
54. Woodland C, Ito S, Granvil CP, Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 2000;68:109-17
55. Nissim I, Horyn O, Daikhin Y, Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res 2006;66:7824-31 (Pubitemid 44289244)
56. Visarius TM, Stucki JW, Lauterburg BH. Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J Pharmacol Exp Ther 1999;289:820-4 (Pubitemid 29191237)
57. Dubourg L, Michoudet C, Cochat P, Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 2001;12:1615-23 (Pubitemid 32674423)
58. Knouzy B, Dubourg L, Baverel G, Michoudet C. Targets of chloroacetaldehyde-induced nephrotoxicity. Toxicol In Vitro 2010;24:99-107
59. Hanly L, Chen N, Rieder M, Koren G. Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. Expert Opin Drug Saf 2009;8:155-68
60. Visarius TM, Bahler H, Kupfer A, Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos 1998;26:193-6 (Pubitemid 28182392)
61. Sayed-Ahmed MM, Aldelemy ML, Hafez MM, Al-Shabanah OA. Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models. Oxid Med Cell Longev 2012;2012:452902
62. Nickel B, Nolte T, Pohl J, The ifosfamide induced nephrotoxicity in rats could be antagonised by L-carnitine without impairment of antitumor responses. Ann Oncol 1998;9(Suppl 2):53-7
63. Nickel B, Nolte T, Pohl J, Pharmaceutical composition comprising ifosfamide and carnitine. US20030040507A1; 2003
64. Sayed-Ahmed MM. L-Carnitine attenuates ifosfamide-induced carnitine deficiency and decreased intramitochondrial CoA-SH in rat kidney tissues. J Nephrol 2011;24:490-8
65. Sayed-Ahmed MM. Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model. Clin Exp Nephrol 2010;14:418-26
66. Graziano F, Bisonni R, Catalano V, Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer 2002;86:1854-7
67. Blum RH, Carter SK. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974;80:249-59
68. O'Donnell MP, Michels L, Kasiske B, Adriamycin-induced chronic proteinuria: a structural and functional study. J Lab Clin Med 1985;106:62-7 (Pubitemid 16046644)
69. Fajardo LF, Eltringham JR, Stewart JR, Klauber MR. Adriamycin nephrotoxicity. Lab Invest 1980;43:242-53 (Pubitemid 10061704)
70. Mimnaugh EG, Trush MA, Gram TE. A possible role for membrane lipid peroxidation in anthracycline nephrotoxicity. Biochem Pharmacol 1986;35:4327-35 (Pubitemid 17204105)
71. Deman A, Ceyssens B, Pauwels M, Altered antioxidant defence in a mouse adriamycin model of glomerulosclerosis. Nephrol Dial Transplant 2001;16:147-50 (Pubitemid 32051489)
72. Pal S, Sil PC. A 43 kD protein from the leaves of the herb Cajanus indicus L. modulates doxorubicin induced nephrotoxicity via MAPKs and both mitochondria dependent and independent pathways. Biochimie 2012;94:1356-67
73. Shahbazi F, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. J Pharm Pharm Sci 2012;15:112-23
74. Ayla S, Seckin I, Tanriverdi G, Doxorubicin induced nephrotoxicity: protective effect of nicotinamide. Int J Cell Biol 2011;2011:390238
75. Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 2000;129:231-4 (Pubitemid 30072641)
76. Ibrahim MA, Ashour OM, Ibrahim YF, Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009;60:373-81
77. Boonsanit D, Kanchanapangka S, Buranakarl C. L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. Nephrology (Carlton) 2006;11:313-20 (Pubitemid 44086876)
78. Erdogan HM, Citil M, Tuzcu M, The effect of L-carnitine administration on doxorubicine induced hepatoxicity and nephrotoxicity in rabbits. Kafkas Univ Vet Fak Derg 2009;15:733-8
79. Radwan RR, Shaban EA, Salem HA, Kenawy SA. Low dose gamma irradiation modifies the effect of l-carnitine, curcumin, garlic powder and green tea extract on doxorubicin-induced nephropathy in rats. Egypt J Hosp Med 2010;40:350-64
80. Izzedine H, Launay-Vacher V, Karie S, Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol 2005;64:315-19 (Pubitemid 41448436)
81. Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol 2009;63:599-604
82. Kolli VK, Abraham P, Isaac B, Selvakumar D. Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy 2009;55:83-90
83. Devrim E, Cetin R, Kilicoglu B, Methotrexate causes oxidative stress in rat kidney tissues. Ren Fail 2005;27:771-3 (Pubitemid 41748133)
84. Sener G, Eksioglu-Demiralp E, Cetiner M, L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol 2006;22:47-60 (Pubitemid 43207809)
85. Mathew TH. Drug-induced renal disease. Med J Aust 1992;156:724-8
86. Balakumar P, Rohilla A, Thangathirupathi A. Gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it? Pharmacol Res 2010;62:179-86
87. Lopez-Novoa JM, Quiros Y, Vicente L, New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011;79:33-45
88. Martinez-Salgado C, Lopez-Hernandez FJ, Lopez-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol 2007;223:86-98 (Pubitemid 47211265)
89. Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol 2003;41:1447-52 (Pubitemid 37088099)
90. Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol 2012;published online22 November2012; doi:10.1007/s00228-012-1452-x
91. Kopple JD, Ding H, Letoha A, L-carnitine ameliorates gentamicin-induced renal injury in rats. Nephrol Dial Transplant 2002;17:2122-31 (Pubitemid 35446667)
92. Kart A, Yapar K, Karapehlivan M, Effects of L-Carnitine on kidney histopathology, plasma and tissue total sialic acid, malondialdehyde and glutathione concentrations in response to gentamicin administration in Balb/C mice. Revue Méd Vét 2006;154:179-84 (Pubitemid 43759579)
93. Al-Shabanah OA, Aleisa AM, Al-Yahya AA, Increased urinary losses of carnitine and decreased intramitochondrial coenzyme A in gentamicin-induced acute renal failure in rats. Nephrol Dial Transplant 2010;25:69-76
94. Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant 2012;published 2012; doi:10.1155/2012/230386
95. O'Connell S, Tuite N, Slattery C, Cyclosporine A-induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci 2012;126:101-13
96. Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. Transplant Proc 2004;36:234S-9S (Pubitemid 38373868)
97. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4:481-508
98. Parra Cid T, Conejo Garcia JR, Carballo Alvarez F, de Arriba G. Antioxidant nutrients protect against cyclosporine A nephrotoxicity. Toxicology 2003;189:99-111 (Pubitemid 36725026)
99. Calvani M, Mosconi L. Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporine-A and others immunosuppressant. EP0722724B1; 1999
100. Cavazza C. Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents. US7897641B2; 2011
101. Bertelli A, Giovannini L, Palla R, Protective effect of L-propionylcarnitine on cyclosporine-induced nephrotoxicity. Drugs Exp Clin Res 1995;21:221-8 (Pubitemid 26073132)
102. Giovannini L, Palla R, Bertelli AA, Cyclosporine nephrotoxicity evaluated by tissue calcium deposition and tubular enzymes is prevented by L-propionylcarnitine in isolated perfused rat kidney. Transplant Proc 1996;28:3122-5 (Pubitemid 26415419)
103. Giovannini L, Migliori M, Taccola D, Acute CYA-induced ATP depletion is prevented by pretreatment with L-propionylcarnitine in isolated and perfused rat kidney. Transplant Proc 1998;30:2026-7 (Pubitemid 28399412)
104. Giovannini L, Migliori M, De Pietro S, L-propionyl carnitine reduces toxicity correlated to cyclosporine-induced intracellular ATP concentrations. Drugs Exp Clin Res 1999;25:173-7 (Pubitemid 29363946)
105. Longoni B, Giovannini L, Migliori M, Cyclosporine-induced lipid peroxidation and propionyl carnitine protective effect. Int J Tissue React 1999;21:7-11 (Pubitemid 29386086)
106. Giovannini L, Migliori M, Origlia N, Acute cyclosporine A nephrotoxicity: protective effect of L-propionylcarnitine on lipid peroxidation in isolated and perfused rat kidney (IPRK). Br J Pharmacol 2001;133(Suppl):S Meeting Abstract: 253P
107. Origlia N, Migliori M, Panichi V, L-propionyl carnitine protects rat kidneys against cyclosporine-A induced lipid peroxidation invivo. Nephrol Dial Transplant 2002;17:172-8
108. Origlia N, Migliori M, Panichi V, Protective effect of L-propionylcarnitine in chronic cyclosporine-a induced nephrotoxicity. Biomed Pharmacother 2006;60:77-81
109. Fattorossi A, Biselli R, Casciaro A, Regulation of normal human polyrnorphonuclear leucocytes by carnitine. Mediators Inflamm 1993;2:S37-41 (Pubitemid 23324383)
110. Winter BK, Fiskum G, Gallo LL. Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br J Cancer 1995;72:1173-9
111. Athanassakis I, Mouratidou M, Sakka P, L-carnitine modifies the humoral immune response in mice after in vitro or in vivo treatment. Int Immunopharmacol 2001;1:1813-22 (Pubitemid 32772651)
112. Alesci S, De Martino MU, Mirani M, L-carnitine: A nutritional modulator of glucocorticoid receptor functions. Faseb J 2003;17:1553-5
113. Fortin G, Yurchenko K, Collette C, Lcarnitine, a diet component and organic cation transporter OCTN ligand, displays immunosuppressive properties and abrogates intestinal inflammation. Clin Exp Immunol 2009;156:161-71
114. De Simone C, Ferrari M, Meli D, Reversibility by L-carnitine of immunosuppression induced by an emulsion of soya bean oil, glycerol and egg lecithin. Arzneimittelforschung 1982;32:1485-8 (Pubitemid 12005559)
115. Kouttab NM, De Simone C. Modulation of cytokine production by carnitine. Mediators Inflamm 1993;2:S25-8 (Pubitemid 23324380)
116. De Simone C, Famularo G, Tzantzoglou S, Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral L-carnitine. Aids 1994;8:655-60 (Pubitemid 24126124)
117. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 2004;183:1673-89 (Pubitemid 44210538)
118. Rudnick MR, Kesselheim A, Goldfarb S. Contrast-induced nephropathy: how it develops, how to prevent it. Cleve Clin J Med 2006;73:75-80.83-7
119. Jabbari M, Mooraki A, Jenabi A, L-carnitine ameliorates contrast media-induced renal injury in rats. Nephrol Dial Transplant 2007;22:vi245-vi50
120. Nephroprotective effects of Carnitine and (PDE5) inhibitor agent against Contrast Media-induced Nephropathy (CMN). 2012.Available from: http://clinicaltrials. gov/ct2/show/NCT01564303
121. Delaney CE, Hopkins SP, Addison CL. Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. Cancer Lett 2007;252:195-207 (Pubitemid 46809790)
122. Pisano C, Vesci L, Milazzo FM, Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine. Clin Cancer Res 2010;16:3944-53
123. Huang H, Liu N, Guo H, L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. PLoS One 2012;7:e49062
124. Bonventre JV, Vaidya VS, Schmouder R, Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010;28:436-40
125. Hosohata K, Ando H, Fujiwara Y, Fujimura A. Vanin-1: a potential biomarker for nephrotoxicant-induced renal injury. Toxicology 2011;290:82-8
126. Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila) 2011;49:720-8
127. Fuchs TC, Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology. Aaps J 2011;13:615-31